Historique
Rapport
Access to hepatitis C testing and treatment for people who inject drugs and people in prisons - A global perspective. Policy brief
Auteur(s) :
OMS / WHO (Organisation mondiale de la santé / World Health Organization)
Année
2019
Page(s) :
20 p.
Langue(s) :
Anglais
Éditeur(s) :
Genève : OMS / WHO
, WHO/CDS/HIV/19.6
Refs biblio. :
13
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Organismes
OMS
Thésaurus géographique
INTERNATIONAL
Thésaurus mots-clés
PRISON
;
HEPATITE
;
DEPISTAGE
;
ACCES AUX SOINS
;
INJECTION
;
PRODUIT ILLICITE
;
POLITIQUE
;
PLANIFICATION SANITAIRE
;
RECOMMANDATION
Résumé :
WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use (PWID). HCV is also a major concern for people detained in prisons and other closed settings - available data demonstrate that one in four detainees are HCV positive.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.